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Magnesium sulfate is often used empirically in cardiac surgical settings. Magnesium sulfate
may cause platelet dysfunction leading to bleeding complication. This editorial commentary
discusses the published study of intra-operative use of magnesium sulfate during off-pump
coronary artery bypass grafting published in this issue of Indian Heart Journal.
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journal homepage: www.elsevier.com/locate/ihjOld adage goes that no medicine is harmless. Every medicine has
adverse effects but when beneﬁts outweigh adverse effects, the
therapeutic index of that medicine is more than 1 and it can be
used clinically. The article published in this issue of Indian Heart
Journal is an eye-opener for cardiac surgeons – particularly those
who practice off-pump coronary artery bypass grafting (CABG)
as the preferred mode of surgical revascularization.1Magnesium
is not seen in the coagulation cascade. It is considered a
harmless drug in the cardiac surgical setting. Magnesium is an
intracellular ion similar to potassium. Patients on long-term
diuretic therapy often develop magnesium deﬁciency which
may lead to cardiac arrhythmias. As it is a systemic vasodilator,
hypotension can happen if administered rapidly. Once deﬁcien-
cy is noted, recommended replacement is 6–8 g over several
hours. There were reports that empirical magnesium sulfate
therapy may improve survival after myocardial infarction2 but it
was not supported by large randomized controlled trial.3
There are evidences to believe that magnesium may protect
cardiomyocytes from ischemia.4 No wonder therefore, during
conventional cardiac surgery, magnesium therapy was used
with the hope of reducing ischemic injury associated with
creating a still motionless heart. Such use of magnesium has
been empiric in cardiac surgery. Preoperative oral magnesium
orotate or IV magnesium sulfate has been usedbefore traditional
on-pump surgery with a hope of reducing myocardial damage by
cardioplegia used during heart surgery using cardiopulmonary
bypass (on-pump CABG). Magnesium sulfate is an important
constituent of recently introduced Del Nido cardioplegia which
offers superior myocardial protection for prolonged period.
After cardiac surgery, empirical magnesium sulfate has been
studied extensively to reduce atrial ﬁbrillation.5 Prophylactic useof magnesium sulfate after cardiac surgery is a grade A
recommendation by European Association of Cardiothoracic
Surgery6 for prevention of atrial ﬁbrillation. Canadian Cardiovas-
cular Society Guideline suggests prophylactic use of magnesium
inpatients with contraindication to beta blocker and amiodarone
forprevention of atrial ﬁbrillation.7The advantageof magnesium
sulfate is that it is a cheap drug with no known adverse effect
other than systemic hypotension till date. In post-cardiac
surgical setting with invasive arterial blood pressure monitoring,
it is relatively easy to administer it as a slow infusion. In fact,
magnesium sulfate postoperatively has been a part of routine
postoperative therapy of the author for the last 14 years of
independent cardiac surgical practice. It has been a practice to
administer the drug when patient is hemodynamically stable.
The study published in this issue of Indian Heart Journal1
brings out one important adverse effect of magnesium sulfate,
i.e. impairing platelet function. This study involved 150 patients
in the magnesium sulfate group compared with 450 patents in
placebo group. There were no differences in the average number
of grafts, operating time, or anticoagulation level between two
groups. There was signiﬁcant increase in intraoperative blood
loss and postoperative bleeding in the magnesium sulfate
group. Magnesium inhibits platelet aggregation at the cellular
level.8 This effect of magnesium sulfate (inhibition of platelet
aggregation) may be responsible for increased bleeding noted in
this study. This is the ﬁrst study reporting bleeding complication
after magnesium sulfate therapy. I could not help but notice that
the reoperation rate in the control group was also high as
compared to our experience. So there may be some component
of surgical technique related factors, which have contributed to
this result. Like any antithrombotic drug, this platelet inhibitory
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patency rate after CABG. Off-pump CABG (OPCAB) techniques
and protocol continue to evolve, particularly in India.9 OPCAB
differs from on-pump CABG as there is a hypercoagulable state
after OPCAB as cardiopulmonary bypass induced coagulopathy
is absent. Antiplatelet therapy after OPCAB is also debatable.9
With the lack of established guideline about OPCAB, many
surgeons use dual anti-platelet therapy after OPCAB. The author
has personal preference for clopidogrel started within 4 h of
surgery in twice daily regime and aspirin added afterwards.9
As a surgeon who practices OPCAB, I read this article and try
to answer the key question 'how this article impacts my practice
of off-pump CABG?' There are evidences to suggest that
preoperative or intraoperative magnesium sulfate may lead to
excessive bleeding and should be avoided as routine empirical
therapy preoperatively. In presence of documented low level of
serum magnesium (in patients with long-term diuretic therapy
or malnutrition) or preoperative arrhythmia, patients may be
given magnesium sulfate replacement before OPCAB. When
preoperative magnesium sulfate therapy is given, platelet
dysfunction must be taken into account during OPCAB. This is
a very similar situation when a patient loaded with antiplatelet
therapy (clopidogrel or prasugrel) is taken up for CABG. These
patients will require meticulous hemostasis from the word go.
We can expect more than expected blood loss during surgery.
After reversing heparin in patients on antiplatelet therapy, the
author would transfuse 4–6 units of platelet concentrate or one
unit of single donor platelet. Similar platelet transfusion must be
given in patients who received magnesium sulfate replacement
before OPCAB. Surgical hemostasis during closure must be
meticulous. So after reading this article, we will follow the same
precaution about impaired platelet function during OPCAB in a
patient who received preoperative magnesium sulfate.
However, I will continue with our routine protocol of using
postoperative magnesium sulfate in the dose of 2 g (diluted in
100 g of saline) twice daily for 2–3 days given as slow infusion
over 1 h. This may be extended more than 3 days if atrial
ﬁbrillation develops or in presence of left ventricular dysfunc-
tion and/or arrhythmia. This postoperative regime has been
followed by the author for more than 14 years of independent
practice. We have reported that a very low rate of reoperation for
bleeding (0.17%) can be achieved in a series of more than 600
consecutive OPCAB10and postoperative magnesium sulfate was
used in all these patients. We would only start magnesium
sulfate infusion postoperatively after hemodynamic stability.
This can be explained that a patient with signiﬁcant bleeding
will be hemodynamically unstable. So when we use magnesium
sulfate in our patients, signiﬁcant bleeding must have subsided
and this can explain our results. I would advice caution of using
magnesium sulfate ina patient with postoperative bleeding with
or without coagulopathy and patients with preoperative
antiplatelet therapy. Also, it is noteworthy that magnesium
sulfate may improve graft patency after CABG. This can be easily
explained that any drug that causes platelet dysfunction will
promote graft patency after CABG. With this study proving
antiplatelet action of magnesium sulfate in clinical settings,
judicious use of magnesium sulfate after OPCAB will protect
from arrhythmia and will also have positive impact of graft
patency. Our experience has proved that magnesium sulfate can
be used postoperatively without any increased risk of bleedingcomplication in OPCAB patients.10 Magnesium sulfate therapy
needs to be further investigated for its antiplatelet action. It will
be interesting to evaluate graft patency in the magnesium
sulfate group versus placebo control. Future study should
include platelet function study in patients receiving magnesium
sulfate and possible synergistic action of magnesium sulfate
with anti-platelet drugs.
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